Participating in a vaccine trial for COVID-19 in Senegal: trust and information. Issue 11 (2nd November 2021)

• Record Type: Journal Article
• Authors: Ridde, V.; Ba, M. F.; Gaye, I.; Diallo, A. I.; Bonnet, E.; Faye, A.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 11(2021)
• Page Start: 3907
• Page End: 3912
• Publication Date: 2021-11-02
• Subjects: Vaccine trial -- COVID-19 -- Senegal -- acceptability -- participation; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.1951097
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: This research aims to understand the level and determinants of people's willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males (AOR = 1.82, 95% CI [1.22–2.72]). Participants who intended to be vaccinated against COVID-19 (AOR = 6.48, 95% CI [4.12–10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (AOR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine trial. Confidence in the vaccine, health personnel, and the government in the fight against the pandemic are key factors in participants' willingness to participate in a vaccine trial in Senegal.